Innate Pharma annual capital expenditures (capex)
2017
2018
2019
2020
2021
2022
2023
2024
2025
Innate Pharma Capital Expenditures (CapEx) Growth & History (IPH)
Innate Pharma's capital expenditures (capex) was €140,000 for fiscal 2025.
View full Innate Pharma company overviewInnate Pharma annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €140,000 | −€251,000 | −64.19% |
| 2024 | 2024-12-31 | €391,000 | €40,000 | +11.40% |
| 2023 | 2023-12-31 | €351,000 | −€184,000 | −34.39% |
| 2022 | 2022-12-31 | €535,000 | −€394,000 | −42.41% |
| 2021 | 2021-12-31 | €929,000 | €22,000 | +2.43% |
| 2020 | 2020-12-31 | €907,000 | −€364,000 | −28.64% |
| 2019 | 2019-12-31 | €1.3M | €398,000 | +45.59% |
| 2018 | 2018-12-31 | €873,000 | −€2.1M | −70.55% |
| 2017 | 2017-12-31 | €3.0M | — | — |
Innate Pharma capital expenditures (capex) trends
Over the last five fiscal years, Innate Pharma's capital expenditures (capex) decreased from €907,000 to €140,000, a change of −€767,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Innate Pharma source filings ↗